Venmax Drugs & Pharmaceuticals Ltd (531015) — FY26 Annual Report | 1 September 2026

Venmax Drugs & Pharmaceuticals Limited submitted its 2025-26 Annual Report to BSE on September 1, 2026, detailing the 37th AGM scheduled for September 26, 2026 via VC/OAVM. The report covers full-year financials, strategic changes including the redesignation of Venkata Rao Sadhanala to Managing Director with ₹30 lakhs annual remuneration, appointment of new directors, and key resolutions. It highlights a significant revenue increase to ₹802.49 lakhs, a profit of ₹24.82 lakhs, and no dividend recommendation. The filing includes statutory auditor approvals, corporate governance details, risk disclosures, and regulatory compliance under SEBI LODR. Key focus areas are financial performance, director changes, and upcoming amalgamation with Hatri Pharma pending NCLT approval.